EBAMed

EBAMed SA is a Geneva-based Swiss medical technology company dedicated to developing innovative, non-invasive solutions for treating heart arrhythmias, particularly ventricular tachycardia. The company’s core technology combines medical devices for proton therapy with advanced motion tracking imaging and software, allowing for precise cardiac motion management during treatment. EBAMed offers a Cardiac Motion Management System that integrates with existing radiation therapy machines to monitor heart movements in real-time. This system uses deep-learning algorithms to ensure accurate targeting of arrhythmogenic tissue while protecting healthy tissue. The company also utilizes proton therapy to non-invasively ablate arrhythmogenic cardiac tissue, providing a quick and painless treatment option suitable for patients of all ages. EBAMed collaborates with leading clinical centers to validate its technology and enhance treatment accuracy and safety. With significant funding and multiple awards, including the Top 100 Swiss Startup Award, EBAMed is positioned to transform the standard of care for heart arrhythmias, making treatments more efficient and accessible for healthcare providers.

• Employees 12
• Founded 2018
• Annual Revenue $3500000
• Total Funding $21557330